Skip to main content
. 2022 Mar 23;91(6):756–771. doi: 10.1002/ana.26339

TABLE 2.

COVID Vaccine Administration and Adverse Events Reported in VAERS in the U.S. Between January 1, 2021 and June 14, 2021

Pfizer Moderna Janssen Any COVID vaccine a
COVID Vaccine Administration 1/1/2021 to 6/14/2021
N doses of vaccine administered 166,981,930 (54%) 128,084,622 (42%) 11,606,202 (4%) 306,907,697
N patients who received at least 1 dose 90,063,644 72,705,161 11,465,768 174,234,573
N patients who received full vaccine course 75,374,466 58,015,983 11,465,768 144,919,339
VAERS Vaccine Side Effect Data 1/1/2021 to 6/14/2021
N side effect entries (inclusive), % of vaccine doses administered 126,901 (0.08%) 148,674 (0.12%) 38,194 (0.33%) 314,610 (0.10%)
N side effect entries (neuro), % of vaccine doses administered 44,896 (0.03%) ^# 42,368 (0.03%) ^! 17,622 (0.15%) #! 105,214 (0.03%)
Age in VAERS‐yr, (median, IQR) 49 (35–64)^# 52 (37–66)^! 44 (31–57)#! 50 (35–64)
Sex in VAERS (% F) 71%^# 74%^! 62%#! 71%
# days from vaccine to symptom onset (median, IQR) 1 (0–2)^# 1 (0–6)^! 0 (0–2)#! 1 (0–3)
N (%) symptoms reported after:
1st dose 50%^ 57%^ 54%
2nd dose 35% 28% 28%
Missing 15% 15% 18%
a

Includes Pfizer, Moderna, Janssen and unspecified manufacturer (n = 841); ^p < 0.001 Pfizer v Moderna, #p < 0.001 Pfizer v Janssen, !p < 0.001 Moderna v Janssen.